Regencell Bioscience
5 hedge funds and large institutions have $260K invested in Regencell Bioscience in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 5 → 5 (0)
0% less ownership
Funds ownership: 0.07% → 0.06% (-0%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
80% less capital inflows, than outflows
Capital inflows: $2.6K | Capital outflows: $12.7K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$2.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tower Research Capital (TRC)
New York
|
-$6.85K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$5.82K |
RGC Hedge Fund Activity: Q3 2022 in Review
5 of the 5,832 institutional investors tracked by Wall St. Rank reported a position in Regencell Bioscience (RGC) for Q3 2022, worth a combined $260K — down 12% from $296K a quarter earlier.
Fund positioning in RGC was balanced in Q3 2022: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $2.6K. The largest seller was Tower Research Capital (TRC), cutting an estimated $6.85K.
- 5 institutional investors held Regencell Bioscience (RGC) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $260K of Regencell Bioscience stock for Q3 2022, down 12% quarter-over-quarter.
- 0 funds opened new Regencell Bioscience positions in Q3 2022 and 0 closed out.
- The largest Regencell Bioscience buyer in Q3 2022 was Morgan Stanley, an estimated $2.6K added.
- The largest Regencell Bioscience seller in Q3 2022 was Tower Research Capital (TRC), an estimated $6.85K sold.
Based on aggregated 13F filings for Q3 2022.